Novo Nordisk Fonden - Understanding and targeting the polyol pathway and fructose dependency of non-small-cell lung carcinoma

Non-small cell lung cancer (NSCLC) is one of the most common and deadliest cancer types. The recent introduction of novel chemo/immuno-therapeutics prolonged the survival of some categories of patients, but there is still great need for new drugs based on a better understanding of the molecular mechanisms underlying the disease. Cancer cells can modify their metabolism to support the malignant properties, and therefore altered metabolic pathways represent an attractive target for drug development in oncology.